Scientists at the Institute of Tropical Medicine, University Hospital Tübingen, Germany, are together with their partner institute CERMEL in Lambaréné, Gabon conducting a clinical trial to test an Canadian Ebola vaccine. A consortium of experts, including scientists from both institutes, was convened by the WHO in August to discuss solutions and strategies for combating the current Ebola crisis.
Of interest at this consortium was one of two forerunning Ebola vaccine candidates which have shown significant promise in animal studies, but have not yet been approved for use in humans.
The candidate VSVΔG-ZEBOV, developed in Canada and produced by the American firm NewLink Genetics is based upon an attenuated Vesicular Stomatitis Virus which has had a single gene from the Zaire Ebola virus inserted. 800 ampules of the vaccine are now provided to the WHO for the clinical trial.
Data from animal studies to date show that animals vaccinated with VSVΔG-ZEBOV are protected against infection with Ebola. Following this success, further studies in humans are warranted to establish a dosage which is safe and well tolerated, whilst simultaneously assessing immunogenicity.
This research will be conducted in institutions across the USA, Europe and Africa and the findings of the phase I study (n=60) in Gabon will be particularly interesting.
They will provide information about how well the vaccine is tolerated by people in the African population; vital for quick distribution of the vaccine in West Africa once a safe and effective dose has been established.
Coordinating doctor of the study Professor Peter Kremsner from the University Hospital in Tübingen is working towards vaccination of the first volunteer in Gabon at the beginning of November.
The first data are projected to be available in just a few weeks after the first vaccination, enabling a decision to be made about whether the vaccine can be introduced into affected West African communities and in which dose.
Medizinische Klinik, Institut für Tropenmedizin
Prof. Dr. Peter Kremsner
Wilhelmstr. 27, 72076 Tübingen
Tel. +49 7071/29-8 71 89, E-Mail firstname.lastname@example.org
Dr. Ellen Katz | idw - Informationsdienst Wissenschaft
Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin
Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy